EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli

Kayoko Hayakawa iD, Yasufumi Matsumura iD, Kohei Uemura, Shinya Tsuzuki, Aki Sakurai, Ryutaro Tanizaki, Koh Shinohara iD, Takehiro Hashimoto, Ryota Hase, Takashi Matono, Hideaki Kato iD, Momoko Mawatari und 5 weitere

Antimicrobial Agents and Chemotherapy · 18.10.2023 · 67 (10)

DOI: 10.1128/aac.00510-23 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.10.2023. Verfasst von Kayoko Hayakawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Disease Control and Prevention Center, National Center for Global Health and Medicine , Tokyo, Japan. Hauptthemen laut MEDLINE: Urinary Tract Infections, Escherichia coli Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Grant-in Aid for Scientific Research, MHLW.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefmetazole is active against extended-spectrum β-lactamase-producing Escherichia coli (ESBLEC) and is a potential candidate for carbapenem-sparing therapy. This multicenter, observational study included patients hospitalized for invasive urinary tract infection due to ESBLEC between March 2020 and November 2021 at 10 facilities in Japan, for whom either cefmetazole or meropenem was initiated as a definitive therapy within 96 h of culture collection and continued for at least 3 d. Outcomes included clinical and microbiological effectiveness, recurrence within 28 d, and all-cause mortality (14 d, 30 d, in-hospital). Outcomes were adjusted for the inverse probability of propensity scores for receiving cefmetazole or meropenem. Eighty-one and forty-six patients were included in the cefmetazole and meropenem groups, respectively. Bacteremia accounted for 43% of the cefmetazole group, and 59% of the meropenem group. The crude clinical effectiveness, 14 d, 30 d, and in-hospital mortality for patients in the cefmetazole and meropenem groups were 96.1% vs 90.9%, 0% vs 2.3%, 0% vs 12.5%, and 2.6% vs 13.3%, respectively. After propensity score adjustment, clinical effectiveness, the risk of in-hospital mortality, and the risk of recurrence were similar between the two groups ( P = 0.54, P = 0.10, and P = 0.79, respectively). In all cases with available data (cefmetazole : n = 61, meropenem : n = 22), both drugs were microbiologically effective. In all isolates, bla CTX-M was detected as the extended-spectrum β-lactamase gene. The predominant CTX-M subtype was CTX-M-27 (47.6%). Cefmetazole showed clinical and bacteriological effectiveness comparable to meropenem against invasive urinary tract infection due to ESBLECs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Tract InfectionsEscherichia coli InfectionsHumansCefmetazoleMeropenembeta-LactamasesEscherichia coliAnti-Bacterial Agents

Stichwörter der Autor:innen

E. coliantimicrobial resistancecarbapenemcephamycinurinary tract infection

Substanzen

CefmetazoleMeropenembeta-LactamasesAnti-Bacterial Agents

Autor:innen und Institutionen

  • Disease Control and Prevention Center, National Center for Global Health and Medicine , Tokyo, Japan.
  • Department of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine , Kyoto, Japan.
  • Interfaculty Initiative in Information Studies, The University of Tokyo , Tokyo, Japan.
  • Faculty of Medicine and Health Sciences, University of Antwerp , Antwerp, Belgium.
  • Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine , Aichi, Japan.
  • Department of Internal Medicine and General Medicine, Ise Municipal General Hospital , Mie, Japan.

ORCID-Profile: Kayoko Hayakawa, Yasufumi Matsumura, Koh Shinohara, Hideaki Kato

Förderung

  • Grant-in Aid for Scientific Research
  • MHLW

Zitieren

APA

Hayakawa, K., Matsumura, Y., Uemura, K., Tsuzuki, S., Sakurai, A., Tanizaki, R., Shinohara, K., Hashimoto, T., Hase, R., Matono, T., Kato, H., Mawatari, M., Hara, H., Hamada, Y., Saito, S., Ohmagari, N., & Doi, Y. (2023). Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00510-23

Vancouver

Hayakawa K, Matsumura Y, Uemura K, Tsuzuki S, Sakurai A, Tanizaki R, et al. Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00510-23

BibTeX
@article{Hayakawa2023,
  author = {Hayakawa, Kayoko and Matsumura, Yasufumi and Uemura, Kohei and Tsuzuki, Shinya and Sakurai, Aki and Tanizaki, Ryutaro and Shinohara, Koh and Hashimoto, Takehiro and Hase, Ryota and Matono, Takashi and Kato, Hideaki and Mawatari, Momoko and Hara, Hiroshi and Hamada, Yukihiro and Saito, Sho and Ohmagari, Norio and Doi, Yohei},
  title = {Effectiveness of cefmetazole versus meropenem for invasive urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00510-23}
}
Kostenlos starten →